Ask AI

Pathway to Peace: Managing Alzheimer’s Disease Agitation With the Patient in Mind

Agitation in Alzheimer’s disease can significantly affect patients and care partners, yet symptoms often go unrecognized or underreported. Listen in for practical insights on identifying and assessing agitation, addressing communication barriers with care partners, and developing individualized management plans that incorporate nonpharmacologic strategies, newly approved medications, and emerging treatment options.

Managing Alzheimer’s Disease Agitation

This transcript was automatically generated from the audio recording and may contain inaccuracies, including errors or typographical mistakes.

Susan Scanland (Dementia Connection LLC): Good afternoon, everyone. We are here to talk about Agitation in Alzheimer's Disease. This has been the majority of my clinical practice for 42 years now as a geriatric nurse practitioner, mostly in long-term care, a topic I am very passionate about. So let us get started.

We know there is a lot of folks aged 65 and older living with Alzheimer's right now. The prevalence, of course, is going to increase. We know this is going to cause more ER visits, more hospitalizations, and also it is going to cost Medicare an absolute fortune.

We know that this is one of the biggest predictors of nursing home placement in folks who have Alzheimer's disease, because the families can deal with the functional things. But when it comes to agitation and aggression that often necessitates placement pretty quickly.

We also know that early agitation is a robust predictor of accelerated progression. They will go downhill much faster, and also mortality.

Brain Mechanisms in AAD
What is going on in the brain? We have got several mechanisms going on. The frontal subcortical circuit and corticocortical dissociations affect both the mood, the affective and also the executive function, the ability to carry out different tasks. Not only that, but we also have neuroinflammation, which we are learning a lot more about. Poor regulation of the serotonergic glutamatergic, which is the main excitatory neurotransmitters, sigma-one and cannabinoid signaling.

Serotonergic pathways start to degenerate and do not function as well. There is also both structural and functional deficits of the frontal anterior and posterior cingulate cortices and the amygdala as well as the hippocampus. And things pretty much get started right in the hippocampus.

We are dealing with alpha receptors. We are dealing with serotonergic, dopaminergic and muscarinic.

How does this result? They misinterpret the threats that are coming in and it affects their mood and their affect and how they act.

Caregiver Barriers to Recognizing and Reporting AAD
What we found out in recent years is that their caregivers do not associate these agitation symptoms with Alzheimer's itself. They have no idea it is connected to what is going on in the brain. So we often have to be the educators of that, because they just say, “Oh, he is just grumpier now, or it is just normal aging or he is just being difficult.”

When we are doing our interviews with our families and patients, we want to go in and ask specifically, “Is there something that they are doing that is bothering you, getting on your nerves?” Before, like I said, they often will be in denial about it. There is still some stigma attached to it. They do not want you to think they are a bad care provider and they are hopeful that this will get better. Not really dealing with it.

They also do not want to upset the person who is suffering from the cognitive loss. They do not want to rock the boat or get them angry, or even look like a bad patient.

They also are unaware that we have got resources to help them, especially for psychiatric behavioral problems. They just felt that there is nothing anybody could do to help me and I have to live with this. So almost this despondent acceptance.

They are not where others are in the same boat that they are. Here is an example. If you had a fever, I would have known what to tell the provider, but at first he just acted more belligerent. I would have known to call, but they do not think about that for agitation symptoms.

Caregiver Terms for Neuropsychiatric Symptoms
Here is some of the terms they might use. They are not going to say, they have got verbal agitation. They will just say he is angry, he is upset, he is melting down, frantic or restless.

Another thing that drives families crazy is the repetitive questions, always asking over and over and over the same things. That is one of the most unsettling things that family members say they have to deal with. Instead of saying, “I have anxiety,” they might say, “I am scared, I am afraid, frantic, upset.”

If you use some of these terms, that might open them up and so that they know that you understand what they are going through emotionally.

Aggression. “He flies off the handle. He is angry.” Apathy. He just goes off to himself and does not seem to really care. They are the kinds of things that you might see. You might hear from your care partners.

What Does Agitation Look Like?
What does agitation look like? It can be motor activity, it can be restlessness, emotional distress or actual aggression. It can be both physical or verbal aggression.

It is interesting that agitation does not mean the same thing as aggression, and many of us think it is the same thing. Agitation can include aggressive behaviors but can occur without aggression, and examples of that are pacing, rocking and repetitive behavior.

International Psychogeriatric Association (IPA) Definition of Agitation in Patients With Cognitive Disorders

The International Psychogeriatric Association, IPA, has defined agitation in persons with cognitive disorders all over. Of course, we are applying this today to Alzheimer's disease. They have to first have a cognitive disorder like mild cognitive impairment or Alzheimer's disease.

In addition, they have to have one or more behaviors that is agitated with emotional distress. It has to be occurring for at least two weeks or more, or it has to have a significant change from their usual baseline behavior. The behaviors are severe and associated with excess distress or disability that is beyond their usual.

It has got to affect their interpersonal relationships, social functioning, or ADL. For example, you can have pacing, which is mild and not really bothering anybody. If it gets severe and it is affecting how they are functioning from an ADL standpoint or how they are relating to others, it could be an example of excessive motor activity.

Once again, many of us have only thought about aggression as being agitation, but excessive motor activity when it impairs ADL, social functioning or relationships, things like pacing, rocking, gesturing, pointing fingers, restlessness, repetitive mannerisms.

Verbal aggression, you all know what that is.

Physical aggression, and these could be activities against other people like grabbing, shoving, pushing, or property, hitting things, kicking things even self-injurious things, destroying property, slamming doors, hitting self. So any of those things. So physical aggression, verbal aggression, and excessive motor activity are the three areas defined by the IPA.

Neuropsychiatric Inventory (NPI) for Assessing Behavioral Changes
Now here is a tool that you can actually use in your clinical practice, the NPI, also known as the Neuropsychiatric Inventory. This is great because it takes the most common symptoms that you will see with Alzheimer's disease or sometimes other dementias. It helps you to communicate with the family members and the patients what is going on. With doing that, they are going to realize this is part of the illness.

This NPI includes hallucinations, delusions, and as the IPA criteria say, agitation, aggression. It also has mood changes like depression, anxiety, euphoria. Apathy, we talked about in the IPA criteria. Disinhibition, which is their irritability/lability, night-time behaviors.

This comes in several different formats. There is an NPI-C for clinicians, the regular NPI-Q, and the Nursing Home version.

Variations of the NPI Questionnaire
It scored a little bit different than the impact questionnaire because this looks at both frequency on a four-point scale and severity as well as distress from a caregiver standpoint. That clues us in on how these behaviors are affecting the person or persons taking care of them.

The NPI questionnaire, and this is one that the caregiver can complete, are self-administered. That is the nice one that they can do ahead of time. And that scored a little bit differently from one to mild to three severe, and they rate their own caregiver distress.

1 Minute to Recognition: The Agitation in Alzheimer’s Screener for Caregivers (AASC)
The Agitation in Alzheimer's Screener for caregivers is the best way to assess agitation in Alzheimer's in a short visit. It was developed by one of my colleagues, Carolyn Clevenger, a nurse practitioner specializing in Alzheimer's and dementias down at Emory.

She developed this just so a clinician can ask a family member basic things, are they repeating motions or behaviors? Are they pacing or restless? You can use the terms, cannot be still. Are they cursing or lashing out? Are they raising their voice or yelling or screaming, resisting assistance, throwing or breaking things and trying to hurt themselves or others?

The question is, do any of these behaviors make their day-to-day functional activities or interactions, their social interactions more challenging?

Once again, this is the best quickest way to assess really quickly for agitation with caregivers. Remember, AASC, the Agitation in Alzheimer's Screener for caregivers.

Establish an Accurate Diagnosis Before Initiating AAD Treatment
Now we want to first be sure that we got an accurate diagnosis, because you do not want to miss the UTI and sepsis thinking that it is agitation in Alzheimer's disease. We have got algorithms for how to deal with it. First, as many of you are aware, you have got to rule out physical causes for agitation. That is another reason why the IPA makes the criteria two weeks or greater. Hopefully, your delirium would be resolved by then.

A nice tool for assessing delirium is the CAM, the Confusion Assessment Method, developed many years before by Sharon Inouye. Basically it looks at things like changes in level of consciousness. Always want to rule out delirium and all the causes because they can be fixed. You do not want to just medicate the agitation.

Pain. There is a PainAD scale.

Depression, I love the Cornell Scale for Depression in Dementia because in my years of nursing home practice and as a dementia consultant to physicians and nurse practitioners in nursing homes, I would see so much depression hidden under the Alzheimer's disease or other dementias. Using the Cornell scale, you actually interview the caregiver or in the case of a nursing home, you go up to the CNAs and say, have you noticed, and it goes through all the symptoms. It is a great scale. I was able to stop a lot of agitation just by treating the depression underneath the diagnosis of dementia.

Psychosis. Hallucinations or delusions typical of Alzheimer's disease, seeing deceased relatives, imposter syndrome, thinking there is somebody else there. Hallucinations, typically visual with Alzheimer's disease. Of course, environmental and psychosocial stressors also.

Is Standard AD Cognitive Treatment In Place?
What I found helped, especially in my nursing home practice and in years of house calls and outpatient, always be sure you are treating with standard FDA-approved meds, the ones we have had around for decades here. Because I have found in my practice that combination therapy really pretty much researched by my colleague, Dr. Ali Atri, basically found if you have got two meds, like a memantine and a cholinesterase inhibitors, they do better, especially from a functional and cognitive standpoint than one drug alone that either of them alone and one drug is better than none.

So combination therapy, as soon as you diagnose, continue until the hospice stage. Even at the hospice stage, there has been some studies showing if you took them off those meds, the agitation would get worse. Be sure, no matter what you are treating the agitation with, you have got this underlying treatment because it does slow things down in most patients.

AAD Decision Tree for HCPs
I developed this Agitation Decision Tree with Dr. George Grossberg, who is one of the pioneers in agitation for many years.

When folks come to you, we are going to ask those questions about symptoms in their language. Is there anything your loved ones doing that is making it challenging. Once again, use the lingo that they talk about the short fuse. Do they get upset? That is a good time to just pull out your NPI. Because the nice thing about having the NPI, it will give you a baseline. You will find out what their frequency is, what their severity is, and you can give it to whoever is there and quantify the frequency or severity.

Then is the important step I talked about before, rule out delirium and its many causes, rule out any other psychiatric disorders like a chronic bipolar schizoaffective. You want to be sure there is nothing else causing the agitation. Do they meet the IPA criteria? If they do, we typically start to use nonpharmacologic first, unless the person is already at a danger to themselves or others, then you do not wait.

If someone is swinging at you, you do not come up to them and say, “Hey, it is time for your lavender or lemon balm hand massage.” Once again, common sense. If they are ready to hurt someone else or you want to be sure you get that taken care of.

If nonpharmacologic works, you have got that NPI, you can follow up on. If it does not work, then you think about pharmacologic treatments. We do have some new options now, which after 42 years of practice in Alzheimer's, I was thrilled to see happen.

Strategies That May Help Reduce Behavioral Symptoms
What are some strategies for behaviors? Even the way a loved one talks or a CNA in a nursing home, affects how the person deals with your conversation. If you argue with them, they are not going to do well.

We really do need to enhance communication skills with family members, but especially in long-term care. Because once again, the turnover is so great with both LPNs and nursing assistants. This is something that has to be ongoing in long-term care.

We need to teach them how to de-escalate situations too. They need to know that these are due to brain changes. It is not because the caregiver is not a good caregiver. It is not because their loved one is a horrible person, but they need to know it is related exactly to the disease itself. So referring them to support groups is very important.

We want to think about simple environmental things. We want to avoid over-stimulation or under-stimulation, boredom versus bright lights and noise and too much happening. We mentioned hand massage does usually work quite nicely. Therapeutic touch, which is not massage but it is working the hands over the person a few inches apart. You can actually find YouTubes on that. It can calm them by just giving them better energy.

Structured or unstructured activities. Exercise is wonderful, especially if it can be outside and if they are safe, obviously with someone else and they are not a fall risk or risk for wandering. Customized music playlists or live music therapy customized. Be sure you get what they like. I have found over the years that relating a person's occupation or hobbies is extremely helpful. What you can do is simulate what they love to do with pictures or with objects. It will often just calm them down. One of my favorite examples is one of my residents who was not my patient for a number of years and I used to see him banging the exit door, making all kinds of ruckus in the recreation room and would just do it almost constantly.

His physician just like, “Well, do not worry about it.” Then I was brought on the case because he was getting ready to be evicted from the facility. I said, “What did he do for a living?” He was a CPA. I said, “Get this man a desk and some ledgers and checkbooks.” They did that. Behaviors totally stopped.

So think about what they did for a living. I have so many stories I can tell you that are quite interesting and entertaining, but time does not allow.

Importance of Individualized Interventions
When you talk to someone, it is very important to know what their triggers are. You want to ask what the stimuli of the agitation are? Is it the time of day? Is it sundowning? Is it location? Is it certain persons? Because depending there may be a person who is a staff member or a home care aide coming in, and they might remind them of somebody they did not like. You do not know what is going on. Sometimes if you shift things around a little bit, you might find the answer.

Maybe this person was a boss in their career, and giving them directions may not go over well. I remember once having a man who built bridges in his state and he had these 25-year-old female CNAs telling him what to do. That just really would get him so upset.

So you got to think about all these things. If it worked at home, you want to continue it in the nursing facility. What worked before, do not knock it. The staff should be able to accommodate that.

Pharmacologic Treatment of AAD
Let us talk about the medications when nonpharmacologic does not work as often happens.

Antipsychotics: Risks in Dementia Use
What about antipsychotics? I know they are used widely in long-term care, because they have had Black Box warnings 20 years now, where we know there is an increased risk of mortality in people who have dementia-related psychosis.

The APAs guidelines have said only when symptoms are severe and they cause significant distress to the patient or pose a danger to the patient or others. In other words, they should not be used to put someone to sleep. They should not be used to make it easier for the staff. They definitely have been overused.

Now they have come down quite nicely since 15 years ago with the long-term care initiatives to decrease antipsychotics. We have to review risks and benefits with the patient and family for the dopaminergic antipsychotics, for things like tardive dyskinesia, risk of CVA, aspiration pneumonia. We got to make families aware of that and we should document that in your notes that you have had that discussion. If you do not see a response after four weeks, medication should be tapered and withdrawn.

Accelerated cognitive decline is very interesting because we know on a mini mental state you will go down probably about a point, 1.5 point, sometimes two points a year. When you have someone on antipsychotics, as we have had, that actually matches exactly the same decline as Alzheimer's does.

For example, if you went down 1.5 point due to Alzheimer's, if you put someone on an antipsychotic, they will go down three points on cognition. Actually maybe you are helping the behaviors, but you are accelerating their cognitive decline. Especially if you want to keep someone at home and save the costs of ALF and nursing home, that is going to shorten your time.

Then you have got the risk of drug-induced parkinsonism, sedation, gait falls, hip fractures and tardive dyskinesia, too. A lot of us do not think about that when we put folks on. It can be life altering to have that.

Brexpiprazole: FDA-Approved Treatment for AAD
Brexpiprazole. It was the first FDA-approved treatment for agitation in Alzheimer's. It is an atypical antipsychotic. It works on serotonin and dopamine, partial agonism at 5-HT1A and D2 receptors and antagonism at 5-HT2A, serotonin and norepinephrine alpha-1b and alpha-2C receptors.

This came out actually three years ago for AAD. It was the first FDA medication approved for AAD. It is an antipsychotic, so it is not indicated for PRN treatment. The target dose two milligrams daily is what showed up in the research studies. The max dose three milligrams, and the starting dose is 0.5 milligrams daily.

Brexpiprazole in AAD: Study 2
What we know in the agitation study, this was a double-blind, well-done research, randomized controlled trial. They titrated this to the maximum dose and
flexible dosing basically going from 0.5 to two. CMAI is the Cohen-Mansfield Agitation Inventory, and down is good. So lower scores are better. Brexpiprazole dropped that down significantly from the placebo.

Brexpiprazole in AAD: Study 3
Another study showed a drop in the Cohen-Mansfield total score, which was the primary endpoint, and a special agitation score also showed improvement.

Dextromethorphan/Bupropion: FDA-Approved Treatment for AAD
Now just in April, a few months ago for Alzheimer's disease agitation came out dextromethorphan/bupropion is the first FDA-approved, non-antipsychotic treatment for AAD. It works on dextromethorphan DM, the old cough syrup.

And this is what happens. It is a high affinity sigma-one agonist and inhibits presynaptic glutamate release. If you recall back in the days when memantine was coming out, glutamate was the main excitatory neurotransmitter in the CNS. Once again we have inhibition of the presynaptic release of that, and also some uncompetitive NMDA receptor antagonism, which also modulates on the other side the postsynaptic glutamate response.

Then we have our well-known bupropion. What that is doing is it is basically slowing the DM metabolism by inhibiting the cytochrome P450 2D6. Again, it was first approved, this same med, for major depressive disorder in 2022. So it has got four years under its belt for treatment of depression.

DM/Bupropion in AAD: Phase II/III ADVANCE-1 Trial
Looking at dextromethorphan/bupropion in agitation in a trial. Basically the change in our famous scale, the Cohen-Mansfield Agitation Inventory, which pretty much covers just about every behavior there is over a five-week period. You actually saw the combination group coming down almost 15 points. They did try a group of bupropion alone, but it was no different than placebo. So that group was dropped because of futility analysis.

DM/Bupropion in AAD: Phase III ACCORD Discontinuation Trial
What they did was they wanted to do another study to follow-up to see what would happen if you discontinued bupropion. Would they remain relapse-free? They looked at over a period of treatment and you could see that in the initial group, it brought down the Cohen-Mansfield score.

Then they were randomized to either get to continue with the DM/bupropion or placebo. You basically see that there was a 3.6-fold reduction in relapse risk if they remained on the dextromethorphan and bupropion. If they went off, there was a more chance that their symptoms would come back.

Xanomeline + Trospium in AAD
There is another investigational compound now, xanomeline plus trospium in agitation. This works on muscarinic agonism and for M4 inhibits cholinergic neurons and lowers dopamine. M1 increases activity of GABAergic prefrontal neurons, which leads to reduced glutamate and dopamine levels, which is a good thing.

Trospium is a peripheral activity, and does not cross the blood-brain barrier. The muscarinic part, the antagonism decreases adverse effects with the xanomeline. This has been used for a couple of years for the treatment of schizophrenia. They are enrolling patients now. If you have anybody, you would want to enroll in that trial.

Cannabinoids in AAD
Cannabinoids. How about that? Who would think? Cannabinoid research. It may increase serotonergic signaling, inhibit glutamate release, which is a good thing. It might reduce excitotoxicity, oxidative stress, which is now being found to be another mechanism going on in the brain, and neuroinflammation.

We have got THC, tetrahydrocannabinol. They try the oil. Up to 7.5 milligrams BID showed decrease in caregiver distress, clinical global impression severity, and actually some help with delusions, agitation, aggression, undesirable symptoms, irritability, apathy and sleep. The dronabinol study, the synthetic receptor agonist, showed a decrease in all domains of the Pittsburgh Agitation scale. So stay tuned and we will see what happens there. It is investigational.

Summary: Key Takeaways
Basically, our key takeaways here are caregivers may be unaware of agitation as a distinct symptom in Alzheimer's. It can result in delayed symptom reporting. We are already missing a couple of years because people do not come to you, even for diagnosis of Alzheimer's, it is usually delayed about two years. You put agitation on top of that, another two years of agitation might be four years before they come to you for help.

So really think about talking layman's verbiage when you talk about these symptoms that are on the NPI and the Cohen-Mansfield inventory that we talked about.

Just pull out the IPA criteria, look at those lists for verbal agitation, physical agitation. Then just like I said, the movements, things that can be non-aggressive types of agitation, the IPA criteria, the NPI.

Remember what I said about the Agitation in Alzheimer's Screener for caregivers, because many of you are out there in primary care crunch time for visits, 20 minutes, 15 minutes. You just want to get that information quickly. The AASC is a wonderful way to do it.

We also know there are now two FDA-approved meds, brexpiprazole and dextromethorphan plus bupropion.